Concerning lung cancer, people who successfully benefit from drugs like erlotinib will certainly develop drug resistance. This is heralded by cancer growth and increasing tumor-related symptoms. Now scientists are investigating a second line of defense by studying the use of the novel AKT inhibitor MK-2206 in combination with erlotinib for patients whose benefit from erlotinib has begun to wane. Results of a Phase II trial will be presented during the 5th Latin American Conference ...Sunday, 29 July 2012
Focusing on Patients With NSCLC, Scientists Hunting For Second-Line Defence
Concerning lung cancer, people who successfully benefit from drugs like erlotinib will certainly develop drug resistance. This is heralded by cancer growth and increasing tumor-related symptoms. Now scientists are investigating a second line of defense by studying the use of the novel AKT inhibitor MK-2206 in combination with erlotinib for patients whose benefit from erlotinib has begun to wane. Results of a Phase II trial will be presented during the 5th Latin American Conference ...
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment